Salvo Health
New York
About Salvo Health
Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes. The company has announced agreements with 771 GI’s, representing 15% of all independent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $22.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2026)
- Website: salvohealth.com
- Phone: [email protected]
Industries & Categories
Health Care
Social Profiles
Canonical: https://fsome.com/organization/salvo-health-14841 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.